2019: The iron-based project team was spin-off from LifeTech and established as Biotyx Medical (Shenzhen) Co., Ltd.

2020: Introduced multiple strategic investors including IDG Capital and Cornerstone Investments, and obtained RMB 160 million in Series A financing

2021: IBS Coronary Scaffold phase II begins enrollment

2022: IBS Coronary Scaffold completes Phase II clinical trial enrollment, IBS Angel™ Iron Bioresorbable Scaffold completes CE registration submission

2023年：IBS Coronary Scaffold completed Phase III clinical trial enrollment, IBS Angel obtained CE certification, and IBS Coronary Scaffold completed CE registration submission